Dr. David J. Einstein, MD
Claim this profileBeth Israel Deaconess Medical Center
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
12 reported clinical trials
29 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
DDRD negative
MMR-d positive
2Prostate Adenocarcinoma
Stage IV
DDRD negative
MMR-d positive
Affiliated Hospitals
Clinical Trials David J. Einstein, MD is currently running
Combination Immunotherapy
for Kidney Cancer
This trial is testing two new drugs, botensilimab and balstilimab, in patients with advanced kidney cancer who haven't been treated before. The new drugs aim to help the immune system better recognize and attack cancer cells. The study will compare these treatments over several months.
Recruiting1 award Phase 212 criteria
Androgen Receptor Antagonists
for Prostate Cancer
The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for participants with recurrent prostate cancer. This study will measure PSMA levels using standard PET/CT scans and participants will receive standard-of-care androgen receptor antagonist monotherapy. The names of the treatment interventions involved in this study are: * Androgen receptor antagonist monotherapy. * PSMA PET/CT scan It is expected that about 15 people will take part in this research study. Participation in this research study is expected to last about 4 weeks.
Recruiting1 award Phase < 1
More about David J. Einstein, MD
Clinical Trial Related1 year of experience running clinical trials · Led 12 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments David J. Einstein, MD has experience with
- Nivolumab
- Apalutamide [Erleada], Darolutamide [Nubeqa], Or Enzalutamide [Xtandi]
- Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
- Supervised Circuit Training
- 177Lu-PSMA-617
- 68Ga-PSMA-11
Breakdown of trials David J. Einstein, MD has run
Prostate Cancer
Prostate Adenocarcinoma
Kidney Cancer
Urothelial Carcinoma
Bladder Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David J. Einstein, MD specialize in?
David J. Einstein, MD focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are DDRD negative.
Is David J. Einstein, MD currently recruiting for clinical trials?
Yes, David J. Einstein, MD is currently recruiting for 4 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that David J. Einstein, MD has studied deeply?
Yes, David J. Einstein, MD has studied treatments such as Nivolumab, Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi], Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan.
What is the best way to schedule an appointment with David J. Einstein, MD?
Apply for one of the trials that David J. Einstein, MD is conducting.
What is the office address of David J. Einstein, MD?
The office of David J. Einstein, MD is located at: Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States. This is the address for their practice at the Beth Israel Deaconess Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.